EML Laser Body Contouring Pilot Study Results
October, 2006
Presented at the ASLMS 2008
Table 1: Average inches by measurement time point: n=16
| Average inches |
Pre-Treatment |
End of Week 2 |
| Waist |
44.14 |
42.86 |
| Hips |
51.28 |
49.94 |
| Right Thigh |
27.46 |
25.75 |
| Left Thigh |
26.93 |
25.43 |
Table 2: Change in circumference measurements from pre-treatment to end of week 2: n=16
|
Waist |
Hips |
Right Thigh |
Left Thigh |
|
| inches |
44.14 to 42.86 in. |
51.28 to 49.94 in. |
27.48 to 25.75 in. |
26.93 to 25.43 in. |
| Change in ins. |
- 1.28 in |
- 1.34 in |
- 1.73 in |
- 1.50 in |
| % change |
-2.85% |
-2.40% |
-4.82% |
-3.88% |
Table 3: Pre-treatment body area measurements in inches: n=16
| Subject |
Waist |
Hip |
Right Thigh |
Left Thigh |
|
1 |
40 |
49 |
31 |
29 |
|
2 |
33.5 |
38.5 |
24 |
23 |
|
3 |
35 |
39.5 |
22 |
20.25 |
|
4 |
98 |
106 |
57 |
57 |
|
5 |
79 |
97 |
57 |
56 |
|
6 |
46.5 |
54.3 |
26 |
24.6 |
|
7 |
33.3 |
39 |
21.5 |
20.1 |
|
8 |
37.6 |
46.5 |
23.2 |
24 |
|
9 |
31.3 |
37 |
19.7 |
19.7 |
|
10 |
33.5 |
41.7 |
23.6 |
23.6 |
|
11 |
38 |
43.3 |
23.2 |
23.2 |
|
12 |
32.7 |
39 |
19.3 |
19.3 |
|
13 |
35.8 |
42.5 |
21.3 |
21.3 |
|
14 |
34.1 |
40.6 |
19.7 |
19.3 |
|
15 |
50.4 |
54.1 |
26.8 |
26.2 |
|
16 |
47.6 |
52.4 |
24 |
24.4 |
Table 4: End of week 2 body area measurements in inches: n=16
| Subject |
Waist |
Hip |
Right Thigh |
Left Thigh |
|
1 |
38.5 |
47.5 |
29 |
28 |
|
2 |
32.5 |
39.5 |
22 |
22 |
|
3 |
35.5 |
40 |
22.5 |
21.5 |
|
4 |
93 |
103 |
53 |
53 |
|
5 |
76 |
93 |
44.5 |
44 |
|
6 |
45.1 |
52.8 |
25.8 |
24.8 |
|
7 |
32.3 |
36.6 |
21.7 |
21.3 |
|
8 |
35.4 |
40.9 |
23.6 |
23.2 |
|
9 |
29.9 |
36.2 |
19.3 |
19.3 |
|
10 |
31.9 |
41.7 |
21.3 |
21.3 |
|
11 |
37.8 |
43.5 |
22.8 |
23.2 |
|
12 |
31.1 |
38.8 |
18.5 |
18.1 |
|
13 |
35.2 |
41.1 |
20.5 |
20.7 |
|
14 |
31.7 |
39.4 |
18.5 |
18.1 |
|
15 |
49.2 |
53 |
25.2 |
24.2 |
|
16 |
50.6 |
52 |
23.8 |
24.2 |
Table 5: Individual subject waist circumference: Pre-treatment to end of week 2: n=16
| Subject |
Pre-treatment |
End of week 2 |
Change in ins. |
% Change |
|
1 |
40 |
38.5 |
-1.5 |
-3.90% |
|
2 |
33.5 |
32.5 |
-1 |
-3.08% |
|
3 |
35 |
35.5 |
0.5 |
1.41% |
|
4 |
98 |
93 |
-5 |
-5.38% |
|
5 |
79 |
76 |
-3 |
-3.95% |
|
6 |
46.5 |
45.1 |
-1.4 |
-3.10% |
|
7 |
33.3 |
32.3 |
-1 |
-3.10% |
|
8 |
37.6 |
35.4 |
-2.2 |
-6.21% |
|
9 |
31.3 |
29.9 |
-1.4 |
-4.68% |
|
10 |
33.5 |
31.9 |
-1.6 |
-5.02% |
|
11 |
38 |
37.8 |
-0.2 |
-0.53% |
|
12 |
32.7 |
31.1 |
-1.6 |
-5.14% |
|
13 |
35.8 |
35.2 |
-0.6 |
-1.70% |
|
14 |
34.1 |
31.7 |
-2.4 |
-7.57% |
|
15 |
50.4 |
49.2 |
-1.2 |
-2.44% |
|
16 |
47.6 |
50.6 |
3 |
5.93% |
Table 6: Individual subject hip circumference: Pre-treatment to end of week 2: n=16
| Subject |
Pre-treatment |
End of week 2 |
Change in ins. |
% Change |
|
1 |
49 |
47.5 |
-1.5 |
-3.16% |
|
2 |
38.5 |
39.5 |
1 |
2.53% |
|
3 |
39.5 |
40 |
0.5 |
1.25% |
|
4 |
106 |
103 |
-3 |
-2.91% |
|
5 |
97 |
93 |
-4 |
-4.30% |
|
6 |
54.3 |
52.8 |
-1.5 |
-2.84% |
|
7 |
39 |
36.6 |
-2.4 |
-6.56% |
|
8 |
46.5 |
40.9 |
-5.6 |
-13.69% |
|
9 |
37 |
36.2 |
-0.8 |
-2.21% |
|
10 |
41.7 |
41.7 |
0 |
0.00% |
|
11 |
43.3 |
43.5 |
0.2 |
0.46% |
|
12 |
39 |
38.8 |
-0.2 |
-0.52% |
|
13 |
42.5 |
41.1 |
-1.4 |
-3.41% |
|
14 |
40.6 |
39.4 |
-1.2 |
-3.05% |
|
15 |
54.1 |
53 |
-1.1 |
-2.08% |
|
16 |
52.4 |
52 |
-0.4 |
-0.77% |
Table 7: Individual subject right thigh circumference: Pre-treatment to end of week 2: n=16
| Subject |
Pre-treatment |
End of week 2 |
Change in ins. |
% Change |
|
1 |
31 |
29 |
-2 |
-6.90% |
|
2 |
24 |
22 |
-2 |
-9.09% |
|
3 |
22 |
22.5 |
0.5 |
2.22% |
|
4 |
57 |
53 |
-4 |
-7.55% |
|
5 |
57 |
44.5 |
-12.5 |
-28.09% |
|
6 |
26 |
25.8 |
-0.2 |
-0.78% |
|
7 |
21.5 |
21.7 |
0.2 |
0.92% |
|
8 |
23.2 |
23.6 |
0.4 |
1.69% |
|
9 |
19.7 |
19.3 |
-0.4 |
-2.07% |
|
10 |
23.6 |
21.3 |
-2.3 |
-10.80% |
|
11 |
23.2 |
22.8 |
-0.4 |
-1.75% |
|
12 |
19.3 |
18.5 |
-0.8 |
-4.32% |
|
13 |
21.3 |
20.5 |
-0.8 |
-3.90% |
|
14 |
19.7 |
18.5 |
-1.2 |
-6.49% |
|
15 |
26.8 |
25.2 |
-1.6 |
-6.35% |
|
16 |
24 |
23.8 |
-0.2 |
-0.84% |
Table 8: Individual subject left thigh circumference: Pre-treatment to end of week 2: n=16
| Subject |
Pre-treatment |
End of week 2 |
Change in ins. |
% Change |
|
1 |
29 |
28 |
-1 |
-3.57% |
|
2 |
23 |
22 |
-1 |
-4.55% |
|
3 |
20.25 |
21.5 |
1.25 |
5.81% |
|
4 |
57 |
53 |
-4 |
-7.55% |
|
5 |
56 |
44 |
-12 |
-27.27% |
|
6 |
24.6 |
24.8 |
0.2 |
0.81% |
|
7 |
20.1 |
21.3 |
1.2 |
5.63% |
|
8 |
24 |
23.2 |
-0.8 |
-3.45% |
|
9 |
19.7 |
19.3 |
-0.4 |
-2.07% |
|
10 |
23.6 |
21.3 |
-2.3 |
-10.80% |
|
11 |
23.2 |
23.2 |
0 |
0.00% |
|
12 |
19.3 |
18.1 |
-1.2 |
-6.63% |
|
13 |
21.3 |
20.7 |
-0.6 |
-2.90% |
|
14 |
19.3 |
18.1 |
-1.2 |
-6.63% |
|
15 |
26.2 |
24.2 |
-2 |
-8.26% |
|
16 |
24.4 |
24.2 |
-0.2 |
-0.83% |